Exercise Intervention for People With Schizophrenia (CREW)

Sponsor
Università degli Studi di Ferrara (Other)
Overall Status
Recruiting
CT.gov ID
NCT06044038
Collaborator
(none)
100
1
2
97
1

Study Details

Study Description

Brief Summary

The study aims to investigate the feasibility and adherence of long-term, moderate-intensity different types of physical activity programs for individuals with schizophrenia. Secondary outcomes are related to the control of non-communicable disease risk factors and the improvement of exercise capacity, body composition and cognitive function.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Physical activity
  • Behavioral: Cognitive rehabilitation program
N/A

Detailed Description

Schizophrenia is a common public health issue that generates a social and economic burden. Individuals affected by schizophrenia experience severe and chronic levels of disability that derive from acute psychotic symptoms, as well as cognitive impairments for which available treatments offer only limited benefits. Moreover, their life expectancy is lower, and they have a higher prevalence of heart diseases risk factors such as obesity, dyslipidemia, smoking, hypertension, diabetes and physical inactivity than the general population. The World Health Organization and the European Mental Health Action Plan 2013-2020 acknowledge the role of physical activity in mental health and encourage the inclusion of lifestyle changes in education and treatment programs for people with mental illness, delivered in primary and secondary healthcare settings. The benefits of regular physical activity are well-recognized and are inversely associated with mortality risk and the incidence of many chronic diseases. Moreover, it plays a critical role in preserving and even improving cognitive function throughout the lifespan. However, people with schizophrenia tend to be less engaged in physical activity programs than the general population and report a range of barriers such as pain, side effects of medications and negative symptoms.

The purpose of this trial is to evaluate the efficacy of an exercise-based intervention program among people with schizophrenia.

All individuals with schizophrenia were screened for eligibility. After verifying inclusion and exclusion criteria and after eligibility is confirmed, written informed consent must be obtained prior to randomization. Baseline patient characteristics (i.e., demographics, medical history, laboratory test results) have been collected and recorded for further assessment. Randomization was performed during the inclusion visit (T1). Randomization will be performed centrally using an internet-based system. The identification number (ID) and the treatment allocation will be assigned by the randomization system. Patients were randomized to physical activity group or usual care by a 2:1 allocation. After the randomization, all participants underwent the same battery of tests and questionnaires according to the study protocol.

All patients were involved in the usual care cognitive program. It was held in weekly 90-minute sessions in a Psychiatric Rehabilitation Center of the Healthcare District of Ferrara. Specialized psychiatric therapists conduct this program with groups of 5-10 participants, based on a Cognitive Remediation model. Each session consists of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks. Tasks include games and exercises (e.g., sudoku, crosswords), as well as discussions aimed at improving short- and long-term memory (i.e., repeating sequences of words and numbers), executive functions, and social cognition, with progressive adaptation of task difficulty. The total number of sessions is 50 for a duration of 12 months. In addition, the intervention arm was involved in a supervised exercise-based program. They could voluntarily participate in a variety of activities such as walking or Nordic walking groups, gentle gymnastics, soccer, swimming, and volleyball. Each activity was scheduled twice a week.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Prevention
Official Title:
Enhancing Functional Capacity and Body Composition of Individuals With Schizophrenia Through a Physical Exercise Intervention
Actual Study Start Date :
Dec 1, 2017
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Physical activity group

Participation in supervised activities such as walking or Nordic walking groups, gentle gymnastics, soccer, swimming, and volleyball. Each activity was scheduled twice a week.

Behavioral: Physical activity
Bi-weekly supervised physical activity intervention

Behavioral: Cognitive rehabilitation program
weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.

Other: Usual care group

Participants in the control group attended weekly 90-minute cognitive rehabilitation sessions according to the usual care procedure in this type of population.

Behavioral: Cognitive rehabilitation program
weekly 90-minute session consisting of welcoming participants, reviewing tasks conducted in the last meeting, and assignment of new pen-and-pencil cognitive and metacognitive tasks.

Outcome Measures

Primary Outcome Measures

  1. Peak Oxygen Uptake (VO2peak) [First assessment at the date of enrolment (baseline) and subsequently every six months until the date of the end of follow-up (up to 2 years)]

    Measurement of cardiorespiratory fitness, reported as ml/kg/min and estimated through a moderate and perceptually regulated 1km treadmill walk test (1k-TWT) or through related short-forms (500m or 200m)

  2. Body Mass Index (kg/m²) [First assessment at the date of enrolment (baseline) and subsequently every six months until the date of the end of follow-up (up to 2 years)]

    Derived from the measurement of weight in kilograms and height in meters

  3. Waist circumference (cm) [First assessment at the date of enrolment (baseline) and subsequently every six months until the date of the end of follow-up (up to 2 years)]

    Measurement of waist circumference

  4. Screen for Cognitive Impairment in Psychiatry (SCIP) [First assessment at the date of enrolment (baseline) and subsequently every six months until the date of the end of follow-up (up to 2 years)]

    Values range from 0 to >100, higher scores mean a better outcome

  5. Frontal Assessment Battery (FAB) [First assessment at the date of enrolment (baseline) and subsequently every six months until the date of the end of follow-up (up to 2 years)]

    Values range from 0 to18, higher scores mean a better outcome

Secondary Outcome Measures

  1. Adherence [From date of enrollment until the date of the end of follow-up (up to 2 years)]

    Number of physical activity sessions attended by the participants and the number of drop-outs

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients diagnosed with schizophrenia for at least 1 year

  • On antipsychotic medications with the same therapeutic regimen for at least 3 months before enrolment

  • Free of symptomatic peripheral arterial occlusive disease and cardiovascular, pulmonary, neurological, metabolic, and orthopaedic disorders that could interfere with physical activity sessions

Exclusion Criteria:
  • Recent modification of the therapeutic regimen

  • Presence of symptomatic peripheral arterial occlusive disease and cardiovascular, pulmonary, neurological, metabolic, and orthopaedic disorders that could interfere with physical activity sessions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Center for Exercise Science and Sport Ferrara Italy 44123

Sponsors and Collaborators

  • Università degli Studi di Ferrara

Investigators

  • Study Director: Gianni Mazzoni, Professor, Università degli Studi di Ferrara
  • Principal Investigator: Simona Mandini, PhD, Università degli Studi di Ferrara

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mandini Simona, Professor, Università degli Studi di Ferrara
ClinicalTrials.gov Identifier:
NCT06044038
Other Study ID Numbers:
  • CSB-23-02
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mandini Simona, Professor, Università degli Studi di Ferrara
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2023